Towards optimal management of ductal carcinoma in situ of the breast

European Journal of Surgical Oncology

Volumn 29, Issue 2, 2003, Pages 191-197

  Mokbel, Kefah ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

DCIS; Radiotherapy; Tamoxifen; Treatment

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; TAMOXIFEN;

AXILLARY LYMPH NODE; BREAST CARCINOMA; BREAST NECROSIS; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL STUDY; DISEASE ASSOCIATION; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LOW LEVEL LASER THERAPY; LYMPH NODE DISSECTION; MASTECTOMY; MEDICAL RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEOMICS; RETROSPECTIVE STUDY; REVIEW; SAFETY; SENTINEL LYMPH NODE BIOPSY; STANDARDIZATION; TUMOR VOLUME;

EID: 0037350290     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2002.1425     Document Type: Review

References (50)

1. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer (Second of Three Parts). New Eng J Med 1992; 327: 390-8.
2. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated by biopsy. Cancer 1995; 76: 1197-200.
3. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996; 275: 913-18.
4. Ikeda DM, Birdwell RL, Daniel BL. Potential role of magnetic resonance imaging and other modalities in ductal carcinoma in situ detection. Magn Reson Imaging Clin N Am 2001; 9: 345-56.
5. Dershaw DD. Imaging guided biopsy: an alternative to surgical biopsy. Breast J 2000; 6: 294-8.
6. Fisher ER, Sass R, Fisher B, Gregorio R, Brown R, Wickerham L. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). II. Relation of local breast recurrence to multicentricity [prior annotation incorrect]. Cancer 1986; 57: 1717-24.
7. Silverstein MJ, Barth A, Poller DN et al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 1995; 31: 1425-7.
8. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 1999; 85: 616-28.
9. Tunon-de-Lara C, de-Mascarel I, Mac-Grogan G et al. Analysis of 676 cases of ductal carcinoma in situ of the breast from 1971 to 1995: diagnosis and treatment - the experience of one institute. Am J Clin Oncol 2001; 24: 531-6.
10. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ: frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989; 63: 618-24.
11. Schwartz GF, Finkel GC, Garcia JC, Patchefsky AS. Subclinical ductal carcinoma in situ of the breast. Treatment by local excision and surveillance alone. Cancer 1992; 70: 2468-74.
12. Veronesi U, Banfi A, Del Vecchio M et al. Comparison of Halsted mastectomy with quadrantectomy, axillary dissection, and radiotherapy in early breast cancer: long-term results. Eur J Cancer Clin Oncol 1986; 22: 1085-9.
13. Fisher B, Bauer M, Margolese R et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985; 312: 665-73.
14. Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman PI and the Consensus Conference Committee. The Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22-25, 1999. The Breast Journal 2000; 6: 4-13.
15. Al-Ghazal SK, Sully L, Fallowfield L, Blamey RW. The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol 2000; 26: 17-19.
16. Singletary SE. Skin-sparing mastectomy with immediate breast reconstruction: the M.D. Anderson Cancer Center experience. Ann Surg Oncol 1996; 3: 411-16.
17. Rubio IT, Mirza N, Sahin AA, Whitman G, Kroll SS, Ames FC, Singletary SE. Role of specimen radiography in patients treated with skin-sparing mastectomy for ductal carcinoma in situ of the breast. Ann Surg Oncol 2000 Aug; 7(7): 544-8.
18. Khoo A, Kroll SS, Reece GP et al. A comparison of resource costs of immediate and delayed breast reconstruction. Plast Reconstr Surg 1998 Apr; 101(4): 964-8.
19. Rogers NE, Allen RJ. Radiation effects on breast reconstruction with the deep inferior epigastric perforator flap. Plast Reconstr Surg 2002; 109: 1919-24.
20. Petit J, Rietjens M, Garusi C. Breast reconstructive techniques in cancer patients: which ones, when to apply, which immediate and long term risks? Crit Rev Oncol Hematol 2001; 38: 231-9.
21. Solin LJ, Kurtz J, Fourquet A et al. Fifteen year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996; 14: 754-63.
22. Fisher B, Constantino J, Redmond C et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993; 328: 1581-6.
23. Fisher B, Dignam J, Wolmark N et al. Lumpectomy and Radiation Therapy for the Treatment of Intraductal Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998; 16: 441-52.
24. Julien J-P, Bijker N, Fentiman S et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomized phase III trial 10853. Lancet 2000; 355: 528-33.
25. George WD, Houghton J, Cuzick J et al. Radiotherapy and tamoxifen following complete local excision in the management of ductal carcinoma in situ: preliminary results from the UK DCIS trial. Proc Am Soc Clin Oncol 2000; abstract 270.
26. Silverstein MJ, Lagios MD. Benefits of irradiation for DCIS: a Pyrrhic victory. Lancet 2000; 355: 510-11.
27. Bijker N, Peterse JL, Duchateau L et al. Risk factors for recurrence and Metastasis after breast-conserving therapy for ductal carcinoma in situ: analysis of the European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001; 19: 2263-71.
28. Kestin LL, Goldstein NS, Martinez AA et al. Mammographically detected ductal carcinoma in situ treated with conservative surgery with or without radiation therapy: patterns of failure and 10 year results. Ann Surg 2000; 231: 235-45.
29. Cutuli B, Cohen-Solal-le Nir C, De Lafontan R et al. Ductal carcinoma in situ of the breast; results of conservative and radical treatments in 716 patients. Eur J Cancer 2001; 37: 2365-72.
30. Sakorafas GH, Tsiotou AG. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives. Cancer Tret Rev 2000; 26: 103-25.
31. Silverstein MJ, Lagios MD, Craig PH et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996; 77: 2267-74.
32. de Mascarel I, Bonichon F, MacGrogan G et al. Application of the van nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: practical considerations. Breast Cancer Res Treat 2000; 61: 151-9.
33. Silverstein MJ, Lagios MD, Groshen S et al. The influence of margin width on local control of ductal carcinoma of the breast. N Engl J Med 1999; 340: 1455-61.
34. Neuschatz AC, DiPetrillo T, Safaii H, Lowther D, Landa M, Wazer DE. Margin width as a determinant of local control with and without radiation therapy for ductal carcinoma in situ (DCIS) of the breast. Int J Cancer 2001; 96: 97-104.
35. Chan KC, Knox WF, Sinha G, Gandhi A, Barr L, Baildam AD, Bundred NJ. Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ. Cancer 2001; 91: 9-16.
36. Fisher B, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993-2000.
37. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 2001; 28: 400-18.
38. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-I Study. J Natl Cancer Inst 1998; 90: 1371-88.
39. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 1998; 16: 2018-24.
40. The ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-9.
41. Zhang Z, Yamashita H, Toyama T et al. Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2002; 74: 47-53.
42. Klauber-DeMore N, Tan LK, Liberman L et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with micro-invasion? Ann Surg Oncol 2000; 7: 636-42.
43. Cox CE, Nguyen K, Gray RJ et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001; 67: 513-19.
44. Luzzi V, Holtschlag V, Watson MA. Expression profiling of ductal carcinoma in situ by laser capture microdissection and high density oligonucleotide arrays. Am J Pathol 2001; 158: 2005-10.
45. Wulfkuhle JD, Sgroi DC, Krutzsch H et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res 2002; 62: 6740-9.
46. Heiken TJ, Farolan M, D'alessandro S, Velasco JM. Predicting the biologic behaviour of ductal carcinoma in situ: an analysis of molecular markers. Surg 2001; 30: 593-601.
47. Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Hortobagyi GN, Lippman SM. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 2002 Jun; 11 (6): 587-90.
48. Dowlatshahi K, Francescatti DS, Bloom KJ. Laser therapy for small breast cancers. Am J Surg 2002; 184: 359-63.
49. Shen KW, Wu J, Lu JS et al. Fiberoptic ductoscopy for breast cancer patients with nipple discharge. Surg Endosc 2001; 15: 1340-5.
50. Mokbel K, Elkak A. The evolving role of mammary ductoscopy. Curr Med Res Opin 2002; 18: 30-2.